New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 30, 2012
10:35 EDTTEVATeva sees 2013 EPS, sales below estimates but long-term cost savings
Teva Pharmaceutical (TEVA) this morning said its FY13 adjusted EPS and net revenue would miss analysts' estimates. For the year, the company is guiding adjusted EPS $4.85-$5.15, well below the consensus of $5.65, on total net revenue $19.5B-$20.5B, also below the consensus of $20.82B. By region, the company forecast U.S. net revenue $10B-$10.6B and Europe revenue $5.5B-$6.1B. Additionally, Teva guided generic medicines net revenue of $10.3B-$10.7B and branded medicines net revenue $7.6B-$8B, including $3.7B-$3.9B in global net revenue for Copaxone and $600M-$700M in global net revenue for Treanda. Teva also provided guidance for FY13 free cash flow of $2.5B-$2.8B, cash flow from operations of $4.5B-$4.8B and adjusted gross profit margin of 59%-61%. On its conference call discussing the 2013 outlook, CFO Eyal Desheh said the company's planned reshaping is expected to yield significant cost savings of $1.5B-$2B over the next five years, and noted that the company will discontinue some legacy R&D programs. The executive also said that Teva is taking a "careful approach" to its Copaxone forecast, guiding for a slight y/y decrease in Copaxone sales. Desheh said the company is looking at the dividend policy on a regular basis with the board, and remains committed to dividends. The company said it is not currently contemplating large acquisitions. Teva CEO Jeremy Levin said that "Going forward you will find that Teva looks like a very different company from the Teva of the past." Following the 2013 guidance and conference call, Teva was positively mentioned at Deutsche Bank. Teva is trading up 50c, or 1.24%, to $40.72 in mid-morning trading.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
08:03 EDTTEVATeva announces U.S. availability of Zecuity transdermal patch system
Subscribe for More Information
August 31, 2015
05:59 EDTTEVAStocks with implied volatility below IV index mean; BIIB TEVA
Stocks with implied volatility below IV index mean; Biogen (BIIB) 37, Teva (TEVA) 31 according to iVolatility.
August 28, 2015
06:01 EDTTEVAStocks with implied volatility below IV index mean; BIIB TEVA
Stocks with implied volatility below IV index mean; Biogen (BIIB) 38, Teva (TEVA) 31 according to iVolatility.
August 27, 2015
06:01 EDTTEVAStocks with implied volatility below IV index mean; BBY TEVA
Stocks with implied volatility below IV index mean; Best Buy (BBY) 34, Teva (TEVA) 33 according to iVolatility.
August 26, 2015
05:56 EDTTEVAStocks with implied volatility below IV index mean; BBY TEVA
Subscribe for More Information
August 25, 2015
17:11 EDTTEVAU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
15:02 EDTTEVAMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTTEVATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
11:27 EDTTEVATeva to refrain from voting at Mylan special meeting
Subscribe for More Information
08:17 EDTTEVATeva multiple low, says Leerink
Subscribe for More Information
August 24, 2015
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
August 21, 2015
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
August 20, 2015
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information
August 18, 2015
08:04 EDTTEVATeva shares reflect Copaxone franchise risk, says Morgan Stanley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use